RxDoctor Payments Data

Ana Garcia, APRN

Family · Oklahoma City, OKNPI 1790166635

Payments from drug & device makers

$843in general payments, 2019–2025

Across 43 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$153
  • Astellas Pharma US Inc$119
  • Pfizer$112
  • AbbVie$108
  • Abbott$77
  • Myriad Women's Health, Inc.$62
  • plus $212 from 8 others

What the payments were for

  • Food & beverage$75690%
  • Education$8710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$843 in reported general payments places this provider in the 65th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$32,351
Medicare patients
85
Services billed
559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin151$243,142
OzempicSemaglutide126$162,050
TrulicityDulaglutide65$82,136
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$59,467
EliquisApixaban42$41,862
RybelsusSemaglutide18$39,507
JanuviaSitagliptin Phosphate22$35,971
MounjaroTirzepatide21$30,770
FarxigaDapagliflozin Propanediol16$26,285
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$11,482
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$8,541
Tresiba Flextouch U-200Insulin Degludec13$7,441
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$6,295
Atorvastatin Calcium485$4,802
Humalog Kwikpen U-100Insulin Lispro23$4,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$33$251,683169 claims
Lilly USA, LLCTrulicity, Mounjaro$33$112,90786 claims
GSKTrelegy Ellipta, Anoro Ellipta$153$70,95096 claims
PfizerEliquis$112$41,86242 claims
AstraZenecaFarxiga, Symbicort$56$29,55230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,026 family providers in Oklahoma.

Other family in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →